Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by B. Paiva
Is This the Time to Introduce Minimal Residual Disease in Multiple Myeloma Clinical Practice?
Clinical Cancer Research
Cancer Research
Oncology
Reply to "Response to "CD20 Positive Cells Are Undetectable in the Majority of Multiple Myeloma Cell Lines and Are Not Associated With a Cancer Stem Cell Phenotype". Haematologica 2012;97(7):1110-1114
Haematologica
Hematology
Related publications
Minimal Residual Disease Assessment in the Context of Multiple Myeloma Treatment
Current Hematologic Malignancy Reports
Cancer Research
Oncology
Hematology
Minimal Residual Disease Testing After Stem Cell Transplantation for Multiple Myeloma
Bone Marrow Transplantation
Transplantation
Hematology
Flow Cytometry in the Diagnosis and Monitoring of Minimal Residual Disease in Multiple Myeloma
Oncogematologiya
Oncology
Hematology
Ficolled Bone Marrow Is Superior to Bone Marrow Buffy Coat for Detection of Minimal Residual Disease in Multiple Myeloma
Hematology
Hematology
A CD138-independent Strategy to Detect Minimal Residual Disease and Circulating Tumour Cells in Multiple Myeloma
British Journal of Haematology
Hematology
Serological Normalisation as a Surrogate Marker for Minimal Residual Disease Negativity in Multiple Myeloma
British Journal of Haematology
Hematology
Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma
JAMA Oncology
Cancer Research
Oncology
Minimal Residual Disease Assessment in Multiple Myeloma: Utility and Feasibility in Resource Constraint Settings of India
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Prospective Molecular Monitoring of Minimal Residual Disease After Non-Myeloablative Allografting in Newly Diagnosed Multiple Myeloma
Blood
Biochemistry
Immunology
Cell Biology
Hematology
